GlassScriptPhysician profile
Brandon Emry
NPI 1164938007
$560.34
in general payments reported to CMS, 2019-2025
15 companies · $36.15 in 2025
The $36.15 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.71 · 2022: $105 · 2023: $206 · 2024: $197 · 2025: $36.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $439.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $144.73 | 2023-2024 | |
| Optinose US, INC. | $84.50 | 2022-2023 | |
| Aerin Medical INC. | $59.59 | 2024 | |
| Baxter Healthcare | $37.68 | 2022 | |
| Convatec INC. | $36.15 | 2025 | |
| Indivior INC. | $28.01 | 2024 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $26.76 | 2024 | Abilify Asimtufii |
| Glaxosmithkline, LLC. | $26.15 | 2022-2023 | Nucala |
| Acclarent, INC | $22.84 | 2023 | Acclarent Aera |
| Braeburn INC. | $21.10 | 2024 | Brixadi |
| Kaleo, INC. | $15.74 | 2023 | Auvi-Q |
| Gilead Sciences, INC. | $15.71 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.26 | 2024 | Uzedy |
| Alkermes, INC. | $14.00 | 2024 | Lybalvi |
| Kowa Pharmaceuticals America, INC. | $13.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Emry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.